Some characteristics of women using SSRI and/or sedatives/hypnotics during early pregnancy
| Drug category | Number | Age <25 vs 25–34 | Age ≥35 vs 25–34 | Parity 1 vs ≥2 | Any smoking | Any previous miscarriage | BMI ≥25 |
|---|---|---|---|---|---|---|---|
| SSRI only* | 10383 | 0.88 (0.83 to 0.95) | 1.25 (1.17 to 1.33) | 1.36 (1.29 to 1.43) | 2.47 (2.27 to 2.70) | 0.99 (0.94 to 1.05) | 1.27 (1.20 to 1.33) |
| SSRI+benzodiazepine | 400 | 0.92 (0.68 to 1.25) | 1.44 (1.06 to 1.94) | 1.04 (0.83 to 1.32) | 4.98 (3.50 to 7.10) | 0.96 (0.73 to 1.27) | 0.92 (0.71 to 1.18) |
| SSRI+HBRA | 305 | 0.98 (0.70 to 1.36) | 1.14 (0.83 to 1.17) | 1.40 (1.08 to 1.81) | 5.48 (3.87 to 7.78) | 0.94 (0.70 to 1.30) | 1.19 (0.89 to 1.60) |
| SSRI+other sedative/hypnotic | 221 | 0.83 (0.54 to 1.28) | 1.42 (0.85 to 2.36) | 1.63 (1.15 to 2.29) | 4.94 (3.08 to 7.52) | 0.97 (0.65 to 1.44) | 1.31 (0.94 to 1.83) |
For each variable, adjustments were made for all the other studied variables. ORs with 95% CIs within brackets comparing exposed women with all other women in the population (n=1 290 672).
*SSRI without sedatives and/or hypnotics but possibly with other concomitant medication.
BMI, body mass index; HBRA, hypnotic benzodiazepine receptor agonist; SSRI, selective serotonin reuptake inhibitor.